Median Technologies has announced a collaboration with a top 10 global oncology pharmaceutical firm on the application of AI to discover predictive imaging biomarkers that could gauge patient responses to a drug candidate.
In this partnership, technologies such as AI, radiomics, and data mining will be brought together by Median’s Imaging Lab division. This collaboration aims to extract digital signatures from images and deliver valuable insights into patient responses to the pharmaceutical company's drug candidate. These findings could serve as companion diagnostics, assisting in identifying those patients who are most likely to benefit from specific drugs.
Based in France, Median Technologies specializes in developing advanced medical imaging software and services for oncology clinical trials, cancer screening, and clinical practice. The company’s flagship product, eyonis, leverages AI to enhance early cancer detection. The company also offers imaging solutions through its iCRO business unit, supporting drug efficacy measurements in oncology clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.